Project Grant 2506212
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Holden, MA 01520, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Vivosphere LLC for $275,000 will support the development of a novel tissue-engineered platform for cancer modeling and drug screening. The project aims to create a more physiologically relevant, high-throughput screening model to improve the translation rate between preclinical and clinical testing of anti-cancer drug candidates. The proposed technology utilizes a 3D hydrogel...
The National Science Foundation (NSF) awarded a $303,864 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics Inc., a for-profit organization located in Ladera Ranch, CA. The grant, awarded on April 1, 2025, aims to develop a platform for discovering and rapidly developing disruptive drug candidates by determining the mechanisms driving diseases at the molecular network level. The project objectives include demonstrating that...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Covalabio Inc. supports the development of cell-penetrating monobodies as a new pharmaceutical intervention for treating certain cancers. The project aims to validate the cell-penetrating monobody technology by designing potent and selective inhibitors targeting oncogenic KRAS mutations in lung, pancreatic, and colorectal cancers. Key technical objectives include...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 was granted to Absco Therapeutics, Inc. (Abscotx) on April 15, 2025 to develop an image-guided intratumoral delivery system for biologic cancer immunotherapies. The project aims to improve localized retention and controlled release of biologic drugs within solid tumors, addressing limitations of current systemic administration methods that suffer from rapid drug...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,991 to Saber Therapeutics, Inc. will support the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins. The resulting NK-TPD cells will be tested for...
The National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) awarded a $190,794 Project Grant to The Research Foundation for the State University of New York (RF SUNY) on October 1, 2024. The grant supports the development of an artificial intelligence (AI)-powered technology to select optimal treatment options for individual cancer patients, with the goal of prolonging patient life. The project aims to establish connections with innovation networks,...
The National Science Foundation (NSF) awarded a $275,000 SBIR Phase I grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Om Therapeutics Inc. in La Jolla, CA. The goal of this project is to enable the discovery of new medicines at an unprecedented rate by empowering researchers to launch drug discovery programs quickly and cost-effectively. The innovation involves the ability to screen billions of unique small molecules against the entire human proteome in a...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award provides $305,000 in funding to Sostos Inc., a minority-owned, woman-owned small business, to develop a cloud-based software platform for identifying multi-omics biomarkers critical for guiding non-small cell lung cancer treatment decisions that can be applied to broad patient populations. The proposed technology leverages advanced artificial intelligence and predictive Boolean...